PD-1 and CTLA-4 dual inhibitor peptides patent

PD-1 and CTLA-4 dual inhibitor peptides

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

Publication details

Recorded assignee: Leidos, Inc.
Publication number: US 12370258 B2
Publication type: Utility patent grant
Publication date: Jul 29, 2025
Filing date: May 12, 2021
CPC classes: A61K31/7105, A61K35/17, A61K39/0011, A61K39/39, A61K39/39558, A61K45/06, A61P35/00, C07K14/70521, C07K14/70532, C07K16/2818, C07K16/2827, C07K7/06, C07K7/08, C12N15/00, A61K2039/505, A61K35/76, A61K38/00, A61P31/04, A61P33/06, Y02A50/30
Inventors: Gutierrez; Gabriel M., Kotraiah; Vinayaka, Phares; Timothy W., Pannucci; James

Party names reflect the published document. Current ownership and legal status can change.

View patent publication →